A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Trial Profile

A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs NKTR 181 (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 26 Sep 2013 Primary endpoint 'Pain-score' has not been met, according to Nektar Therapeutic media release.
    • 26 Sep 2013 Preliminary top-line results announced in a Nektar Therapeutic media release.
    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top